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The oligomeric nature of the viral envelope proteins has been partly held responsible for the observed differences in
neutralization sensitivity between primary and laboratory-adapted strains of human immunodeficiency virus type 1 (HIV-1).
However, recent evidence suggests that host factors can also modify the sensitivity of HIV-1 particles to neutralization.
Having previously demonstrated that the acquisition of host-encoded intercellular adhesion molecule (ICAM)-1 proteins by
newly formed viruses has a functional significance for the life cycle of HIV-1, we investigated whether the acquisition of
host-derived ICAM-1 by HIV-1 could affect the virus sensitivity to neutralization. In this study, we have first shown that the
physical presence of host cell membrane ICAM-1 on HIV-1 was not modifying virus sensitivity to neutralization by either two
different anti-gp120 monoclonal antibodies (0.5b and 4.8D) or soluble CD4. However, the ability of the F105 anti-gp120
monoclonal antibody (specific for the CD4-binding site) to neutralize ICAM-1-bearing virions was diminished when target
cells were pretreated with an lymphocyte function-associated antigen-1 (LFA-1)-activating antibody. Interestingly, ICAM-1/
POS progeny viruses were found to be slightly more resistant to neutralization by individual human sera in target cells
expressing a low-affinity form of LFA-1 than viruses devoid of host-encoded ICAM-1 proteins. This resistance was markedly
enhanced when target cells expressed an activated LFA-1 form on their surface. These results suggest that the interaction
between virally embedded host ICAM-1 and target cell surface LFA-1 should be considered a factor modulating neutralization
sensitivity of HIV-1 by human sera from HIV-1-infected individuals. © 2000 Academic Press
a
G
f
t
p
c
a
1
s
(
m
p
C
H
a
G
H
bINTRODUCTION
Like other retroviruses, human immunodeficiency vi-
rus type 1 (HIV-1) buds out from the host cell through the
cytoplasmic membrane. During this budding process,
the viral lipid membrane is taken directly from the
plasma membrane. It is also at this step that nascent
virions acquire their external (gp120) and transmem-
brane (gp41) envelope glycoproteins, both of which are
targeted to the cell surface by the secretory pathway
(Hunter, 1994). In addition to these virally encoded Env
glycoproteins, HIV-1 also incorporates a wide array of
constituents of cellular origin (reviewed in Tremblay et
al., 1998). Among these are the major histocompatibility
complex class II (MHC-II) molecules (HLA-DR, -DP, and
-DQ determinants), b2-microglobulin, CD44, CD55, CD59,
s well as lymphocyte function-associated antigen-1
LFA-1) and ICAM-1 adhesion molecules (Benkirane et
l., 1994; Cantin et al., 1996; Castilletti et al., 1995; Fais et
1 To whom reprint requests should be addressed at Unite´
’ImmunoRe´trovirologie Humaine, Centre de Recherche en Infectiolo-
ie, RC709, Centre Hospitalier Universitaire de Que´bec, Pavillon CHUL,
705 boul. Laurier, Ste-Foy, Que´bec, Canada G1V 4G2. Fax: (418)
54-2715. E-mail: Michel.J.Tremblay@crchul.ulaval.ca.
493l., 1995; Henderson et al., 1987; Hoxie et al., 1987; Lee
uo and Hildreth.,1995; Saifuddin et al., 1995).
Over the past few years, these molecules have been
ound to retain their biological functions after incorpora-
ion on the surface of budding viral particles. For exam-
le, HIV-1-incorporated CD55 and CD59 complement
ontrol proteins have been reported to protect virions
gainst complement-mediated virolysis (Saifuddin et al.,
995). Cellular HLA-DR embedded in HIV-1 has been
hown to efficiently present superantigens to T-cells
Rossio et al., 1995). Some HIV-1-acquired cell adhesion
olecules have also been shown to be functionally im-
ortant at the level of the viral life cycle. Incorporation of
D44 from activated cells in the envelope of budding
IV-1 helps the virus to attach to cells bearing hyaluronic
cid, the natural ligand for CD44, on their surface (Lee
uo and Hildreth, 1995). Increased incorporation of host
LA-DR and ICAM-1, after stimulation of producer cells
y g-IFN, enhances HIV-1 infectivity for CD4-negative
cells (Castilletti et al., 1995). The addition of anti-LFA-1
antibodies to neutralizing sera has been demonstrated
to potentiate their blocking activity against infection by
cell-free viruses, thus suggesting a role for LFA-1 in
HIV-1 infection (Gomez and Hildreth, 1995). Recently, we
developed a transient transfection and expression sys-
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494 FORTIN ET AL.tem to produce virus particles differing only by the ab-
sence or the presence of a specific cellular molecule in
their envelope. With this system, we determined that the
acquisition of host HLA-DR1 and ICAM-1 molecules by
HIV-1 is associated with an increase in viral infectivity
ranging from 1.6- to 2.3-fold and from 5- to 10-fold, re-
spectively (Cantin et al., 1997; Fortin et al., 1997). Using a
imilar technical approach, Rizzuto and Sodroski (1997)
orroborated our findings with virion-bound host ICAM-1
roteins.
The first step in the HIV-1 replicative cycle is the
ttachment to the target cell. This stage is achieved
hrough the interaction between the viral gp120 protein
nd the cell surface CD4 protein (Dalgleish et al., 1984;
latzmann et al., 1984). Such an interaction then creates
high-affinity binding site for the appropriate chemokine
eceptor (Lapham et al., 1996; Trkola et al., 1996), acting
s a necessary cofactor (Alkhatib et al., 1996; Choe et al.,
996; Deng et al., 1996; Doranz et al., 1996; Dragic et al.,
996; Feng et al., 1996). Ultimately, through a conforma-
tional change, the gp41 fusion peptide is exposed, an
event necessary to lead to the fusion between viral and
cellular membranes (Binley and Moore, 1997; Weissen-
horn et al., 1997). Virion-acquired ICAM-1 molecules are
thought to act at the early steps of the attachment of the
virus by increasing the avidity of the virus–cell conjugate
and, thereby, complements of the CD4–gp120 interaction
(Fortin et al., 1997). The crucial role played by the inter-
action between virion-bound ICAM-1 and cell surface
LFA-1 in the process of virus infection is further indicated
by the demonstration that target cells expressing LFA-1
with a high-affinity conformational state for its counter-
receptor ICAM-1 are more susceptible to infection with
ICAM-1-bearing HIV-1 particles (Fortin et al., 1998).
It is now well established that primary isolates of HIV-1
are more resistant to neutralization induced by anti-HIV-1
antibodies and soluble CD4 (sCD4) than laboratory-
adapted strains (Matthews, 1994; Moore et al., 1995).
However, the precise reason for this difference is not
well understood. Some studies have reported that the
affinity of gp120 for sCD4 was from 10 to 30 times lower
for primary isolates of HIV-1 than for laboratory strains
(Moore et al., 1992), whereas others have suggested that
the level of gp120 per virion was much higher on primary
viral isolates (Karlsson et al., 1996). However, it should be
noted that this issue is still controversial as some inves-
tigators have demonstrated that increased envelope
spike density and stability are not responsible for the
higher level of neutralization resistance shown by pri-
mary isolates of HIV-1 (Karlsson et al., 1996). From these
studies, it can be postulated that the intrinsic character-
istics of gp120 from primary and laboratory HIV-1 iso-
lates must be in part responsible for the observed differ-
ences in neutralization sensitivity. However, it is quite
possible that the nature of host-derived proteins embed-
ded in newly formed progeny viruses might also repre-
i
csent a key factor in the observed change in neutralization
sensitivity. This is reminiscent of the fact that most lab-
oratory viral isolates are expanded in T-lymphoid cell
lines, whereas virus stocks of HIV-1 clinical strains are
mainly produced in mitogen-stimulated primary mononu-
clear cells.
With the help of our recently described transient trans-
fection and expression system (Fortin et al., 1997), we
have produced isogenic virus particles bearing or not
bearing host-derived ICAM-1 on their surfaces to evalu-
ate the role of this adhesion molecule in the neutraliza-
tion sensitivity of HIV-1. Using a panel of gp120-directed
monoclonal antibodies, sCD4, and individual sera, we
found that the acquisition of cellular ICAM-1 by nascent
HIV-1 particles is a factor affecting sensitivity to neutral-
ization. Moreover, for the first time, we have determined
that neutralization sensitivity of ICAM-1-bearing virions is
even more significantly altered by the conformational
state of LFA-1 that is expressed on the surface of target
cells.
RESULTS
Elaboration of a reporter gene-based system to
evaluate neutralization sensitivity of HIV-1
We previously reported that virion-embedded host
ICAM-1 can interact with its counterreceptor LFA-1 on
the surface of the target cell and that this association
resulted in an increase in HIV-1 infectivity (Fortin et al.,
1997). We thus wondered whether this additional inter-
action could render these virions less sensitive to neu-
tralization. Our primary objective was to develop a re-
porter gene-based neutralization assay. The efficiency
and sensitivity of luciferase-based assays to monitor
single-round infection event are widely accepted. We
have already demonstrated that HIV-1 infection of 1G5, a
cell line containing an HIV-1 LTR-driven luciferase gene,
leads to a dose-dependent increase in reporter gene
activity 48 h after virus infection (Fortin et al., 1997). In
this system, the production of the viral Tat protein by de
novo virus infection mediates a rapid and strong up-
regulation of HIV-1 LTR-driven luciferase activity, allow-
ing the quantitative evaluation of single-cycle infection
events. We also demonstrated that infection of PM1 cells
with recombinant luciferase-encoding viruses culmi-
nates in a strong increase in luciferase activity at 72 h
postinfection (Fortin et al., 1998; Paquette et al., 1998).
To evaluate the efficiency of this system to measure
virus neutralization sensitivity, we first used serum from
an HIV-1-positive individual to neutralize HIV-1NL4-3 parti-
les bearing or not bearing host ICAM-1 proteins on their
urfaces (termed ICAM-1/POS and ICAM-1/NEG, respec-
ively). For this purpose, standardized amounts of ICAM-
/NEG and ICAM-1/POS virions were incubated withncreasing concentrations of a human serum before in-
ubation with 1G5 cells. Virus infection were next mon-
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495ENV-INCORPORATED ICAM-1 AND HIV-1 NEUTRALIZATIONitored by measuring luciferase activity from 1G5 cells. As
depicted in Fig. 1A, higher concentrations of sera re-
sulted in a gradual decrease in the level of HIV-1 infec-
tion, as determined by HIV-1 LTR-dependent luciferase
activity. Similar results were obtained when PM1 cells
were infected with ICAM-1/NEG or ICAM-1/POS mac-
rophage-tropic viruses (Fig. 1B). In agreement with our
previous reports, ICAM-1/POS virions were still more
infectious than their ICAM-1/NEG counterparts (Fortin et
l., 1997; Fortin et al., 1998). The results from this set of
xperiments indicate that the present reporter gene-
ased system is appropriate to measure neutralization
ensitivity of HIV-1. This system was found to be sensi-
ive, reproducible, and rapid, requiring no more than 48
o 72 h for completion.
eutralization sensitivity of virions bearing host
CAM-1 proteins is influenced by the nature
f the neutralizing monoclonal antibody
nd the LFA-1 activation state
Initially, ICAM-1/NEG and ICAM-1/POS virus stocks
ere treated with increasing concentrations of various
nti-gp120 antibodies and sCD4 and compared in terms
f susceptibility to neutralization. The incorporation of
CAM-1 on HIV-1 particles did not affect the sensitivity to
eutralization by 0.5b and 4.8D, two anti-gp120 monoclo-
nal antibodies (Figs. 2A and 2B). We also tested sCD4
because it is considered to be one of the most potent
inhibitor of laboratory-adapted strains of HIV-1 (Clapham
et al., 1989; Deen et al., 1988). Again, a comparable
sensitivity to sCD4-mediated neutralization was noticed
for progeny viruses bearing or not bearing host-encoded
ICAM-1 proteins on their surfaces (Fig. 2C). Altogether,
these data suggest that the sensitivity of HIV-1 particles
to neutralization by anti-gp120 monoclonal antibodies
tested and sCD4 is not altered by the incorporation of
host cell constituents such as ICAM-1.
Previous studies have elegantly shown that LFA-1 can
switch from a low- to a high-affinity conformational state
for its counterreceptor ICAM-1, a conformational change
that is induced on T-cell activation through the T-cell
receptor (Dustin and Springer, 1989). On the basis of our
recent observation indicating that expression of the high-
affinity conformational state of LFA-1 on the surface of
target cells rendered these cells more susceptible to
infection by ICAM-1/POS virions (Fortin et al., 1998), we
were next interested in determining whether the confor-
mational state of LFA-1 could affect neutralization sensi-
tivity of ICAM-1/POS progeny viruses. To attain this goal,
before incubation with HIV-1 particles, 1G5 cells were
treated with NKI-L16, an antibody known to induce a
high-affinity LFA-1 conformational state for ICAM-1
(Keizer et al., 1988). It should be mentioned that although
LFA-1 has signaling properties, the treatment of 1G5
s
wcells with NKI-L16 has no effect on HIV-1 LTR-driven
luciferase activity in 1G5 cells (data not shown; Paquette
et al., 1998). Neutralization sensitivities of isogenic
ICAM-1/NEG and ICAM-1/POS viruses to 0.5b, 4.8D, and
CD4 were comparable even in the presence of the
ctivated form of LFA-1 on the surface of target 1G5 cells
Figs. 2D–2F).
We next tested F105, a monoclonal antibody directed
gainst a conformational epitope of gp120 mapping to
he CD4-binding site (Posner et al., 1993). Similar sensi-
ivity to neutralization by F105 was observed when infec-
ion was performed with either ICAM-1/NEG or ICAM-1/
OS virus preparations (Fig. 3A). However, when 1G5
ells bearing the activated form of LFA-1 were used as
argets, ICAM-1/POS progeny viruses were found to be
FIG. 1. Infection with ICAM-1/NEG and ICAM-1/POS virions is neu-
tralized by an individual sera. Similar amounts of ICAM-1/NEG (E) and
ICAM-1/POS (h) T-tropic (strain NL4-3) or macrophage-tropic (lucif-
erase-encoding viruses pseudotyped with JR-FL envelope) strains of
HIV-1 (10 ng of p24) were first incubated with increasing concentrations
of a human sera. These T- and macrophage-tropic viral strains were
then used to infect 1G5 (A) and PM1 (B) cells, respectively. After an
incubation period at 37°C of 48 h for 1G5 and 72 h for PM1, cells were
next lysed and luciferase activity was monitored. Results are the
mean 6 SD for triplicate samples and are representative of three
independent experiments.ignificantly more resistant to neutralization by F105 than
ere ICAM-1/NEG viruses (Fig. 3B). To explore the role
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496 FORTIN ET AL.of the interaction between virus-embedded ICAM-1 and
high-affinity LFA-1 in the observed differences in sensi-
tivity to neutralization, an anti-ICAM-1 antibody was
added to the virus–cell mixture during the incubation
period with F105. As depicted in Fig. 3C, a similar pattern
of neutralization by F105 for both ICAM-1/NEG and
ICAM-1/POS virus preparations was observed after
blocking of the ICAM-1/LFA-1 interaction. These data
indicate that the reduced sensitivity to neutralization con-
ferred by virally embedded host ICAM-1 is dependent on
both the LFA-1 activation state and the viral epitope(s)
recognized by the neutralizing agent.
The LFA-1-activated state on target cells also
influences the neutralization sensitivity of ICAM-1/
POS virions to sera from HIV-1-infected persons
To more closely parallel physiological conditions, we
next compared the sensitivity of ICAM-1/NEG and ICAM-
1/POS virus stocks to neutralization by sera from HIV-1-
infected individuals. 1G5 cells expressing or not the
high-affinity conformational LFA-1 state for ICAM-1 were
again used as targets in these experiments. Individual
FIG. 2. Effect of the LFA-1 activation state on neutralization of ICAM
sCD4. Identical amounts of ICAM-1/NEG (E) and ICAM-1/POS (h) viru
and D), 4.8D (B and E), and sCD4 (C and F) for 30 min at 37°C in 96-we
NKI-L16 at 1 mg/ml (D–F) for 30 min at 37°C. 1G5 cells (105) were next a
ells were then lysed, and luciferase activity was monitored. Inhibitio
nhibition 5 [1 2 (treated virus/untreated virus) 3 100%]. Results show
ndependent experiments.sera from three HIV-1-infected individuals at various
stages of the disease were used for this series of exper-iments (Table 1). When using sera from HIV-1-infected
individuals and target 1G5 cells expressing LFA-1 in the
low-affinity state for ICAM-1, ICAM-1/POS viruses were
almost as sensitive to neutralization as ICAM-1/NEG
viruses (Figs. 4A–4C). However, surface expression of
the activated form of LFA-1 on 1G5 cells, by means of
treatment with NKI-L16, rendered ICAM-1/POS HIV-1 par-
ticles markedly more resistant to neutralization by sera
from HIV-1-infected persons than ICAM-1/NEG viruses
(Figs. 4D–4F). For example, serum from patient P017
when diluted at 1:256 could inhibit infection with ICAM-
1/NEG virions by 73%, whereas infectivity of ICAM-1/POS
HIV-1 particles was decreased by 8% (Fig. 4F). The se-
rum neutralization curves indicates that 3- to 13-fold
higher sera concentrations were required to achieve a
50% neutralization (IC50) of ICAM-1/POS viruses com-
pared with the IC50 value for ICAM-1/NEG virus stocks
(Table 1). The sum of these experiments underscores the
importance of virally acquired host proteins such as
ICAM-1 in HIV-1 sensitivity to neutralization by sera of
HIV-1-infected individuals. It also provides information on
the influence of the target cell with regard to neutraliza-
and ICAM-1/POS viruses by monoclonal anti-gp120 antibodies and
ng of p24) were first treated with increasing concentrations of 0.5b (A
s. In parallel, 1G5 cells were either left untreated (A–C) or treated with
o each well, and plates were incubated for an additional 48 h at 37°C.
us infection was calculated with the following formula: percentage of
the mean 6 SD for triplicate samples and are representative of three-1/NEG
ses (10
ll plate
dded t
n of virtion sensitivity of progeny virions carrying host-encoded
molecules on their surfaces.
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497ENV-INCORPORATED ICAM-1 AND HIV-1 NEUTRALIZATIONICAM-1 incorporation can also affect the
neutralization sensitivity of a primary,
macrophage-tropic strain of HIV-1
To determine that the observed effect of virion-embed-
FIG. 3. The increased resistance to neutralization of ICAM-1/POS
virions with target cells expressing the activated LFA-1 form is inhibited
by treatment with an anti-ICAM-1 antibody. Identical amounts of ICAM-
1/NEG (E) and ICAM-1/POS (h) viruses (10 ng of p24) were first treated
with increasing concentrations of F105 for 30 min at 37°C in 96-well
plates in the absence (A and B) or the presence (C) of an anti-ICAM-1
antibody (clone RR1/1.1.1 at 20 mg/ml). In parallel, 1G5 were either left
ntreated (A) or were treated with NKI-L16 at 1 mg/ml (B and C) for 30
min at 37°C. Thereafter, 1G5 cells were added to each well, and plates
were incubated for an additional 48 h at 37°C. Cells were then lysed,
and luciferase activity was monitored. Inhibition of virus infection
was calculated as described in Fig. 2. Results are the mean 6 SD
for triplicate samples and are representative of three independent
experiments.ded ICAM-1 on neutralization sensitivity was neither cell-
type specific nor restricted to T-tropic HIV-1 isolates (X4),our next set of experiments was performed with an
established CCR5-positive human T lymphoid cell line
(i.e., PM1) and virions pseudotyped with the envelope
proteins from the primary macrophage-tropic JR-FL viral
strain. Virus preparations bearing or not host-derived
ICAM-1 proteins on their surfaces were incubated with
PM1, a cell line susceptible to infection with both T- and
macrophage-tropic viruses, in the presence of the hu-
man serum from patient P054. Interestingly, ICAM-1/POS
virions were found to be more resistant to neutralization
than ICAM-1-free progeny viruses even when cells were
expressing the low-affinity form of LFA-1 on the surface
of PM1 cells (Fig. 5A). The sensitivity to neutralization of
ICAM-1/POS virions bearing the macrophage-tropic
JR-FL envelope proteins was even more greatly reduced
by induction of the LFA-1 high-affinity state on the sur-
face of PM1 cells (Fig. 5B). These results indicate that the
increased resistance to neutralization conferred by the
combined action of virally acquired host ICAM-1 and cell
surface-activated LFA-1 is a phenomenon that is not
restricted to viruses of a particular tropism.
DISCUSSION
Multifactorial parameters are governing sensitivity of
HIV-1 to neutralization, and the exact nature of these
factors is still ill defined. In the present study, our primary
goal was to determine whether the acquisition of host-
derived molecules by progeny viruses can modulate the
neutralization sensitivity of HIV-1. This investigation was
prompted by our previous reports showing that incorpo-
ration of cellular ICAM-1 in newly formed virions was
associated with an increase in viral infectivity and that
T-cells expressing the high-affinity form of LFA-1 on their
surfaces were more susceptible to infection by ICAM-1-
bearing HIV-1 particles (Fortin et al., 1997, 1998). This last
observation is of physiological relevance considering
that the activated form of LFA-1 is most likely expressed
on the surface of a fairly high proportion of lymph node-
TABLE 1
Characteristics of Sera Donors and Neutralization Sensitivity of
CAM-1/NEG and ICAM-1/POS Virus Stocks when 1G5 Cells
xpressing the Activated LFA-1 Form Are Used as Targets
Patient
Age
(yr)
CD4
(cells/mm3) Therapy
Resistance
ratioa
P032 46 632 AZT-ddC 3.3
P054 39 238 AZT-ddC-Indinavir 6.7
P017 33 8 AZT-ddC-Indinavir 13
a Relative resistance ratios of studied virus preparations to sera
eutralization in 1G5 cells expressing the high-affinity LFA-1 form were
alculated as [(IC50 ICAM-1/POS)/(IC50 ICAM-1/NEG)]. The 50% neutral-
ization titers (IC50) were defined as the sera dilution at which there was
a 50% reduction in luciferase activity compared with uninfected cells
and were calculated from the neutralization curves.
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498 FORTIN ET AL.associated T lymphocytes because antigenic stimula-
tion, a process known to induce the high-affinity state of
LFA-1 for ICAM-1, is taking place in such anatomical
sites (Parrot and Wilkinson, 1981).
The use of susceptible cells containing a reporter
gene (secreted alkaline phosphatase) under the control
of the regulatory elements of HIV-1 (LTR) has been re-
cently shown to be an interesting alternative approach to
assess neutralization sensitivity of simian immunodefi-
ciency viruses (Means et al., 1997). The 1G5 cell line, a
Jurkat derivative stably transfected with two copies of a
construct containing the luciferase reporter gene under
the control of the HIV-1SF2 LTR (Aguilar-Cordova et al.,
994), was used as a target to develop a novel neutral-
zation assay. We were confident that this cell line would
e appropriate to assess neutralization based on the
otion that infection of 1G5 cells with HIV-1 permits to
onitor single-cycle virus infection events (Fortin et al.,
997, 1998). However, it should be noted that this assay
s restricted to the use of T-cell line-adapted X4 strains of
IV-1 given that 1G5 cells do not express CCR5 on their
urface (Berger et al., 1998). Therefore, to measure the
eutralization sensitivity of macrophage-tropic (R5)
FIG. 4. Sensitivity to neutralization by sera from HIV-1-infected indiv
ewly formed HIV-1 particles. Similar amounts of ICAM-1/NEG (E) and
7°C with twofold serial dilution of sera from three HIV-1-infected sub
hese experiments, 1G5 target cells were either left untreated (A–C) or
next added to the virus–sera mixture, and infection was allowed to pro
was monitored. Inhibition of virus infection was evaluated as described
are representative of three independent experiments.trains of HIV-1, we also tested PM1 cells in a neutral-
zation assay using recombinant luciferase-encoding
l
orogeny viruses pseudotyped with the JR-FL envelope.
hese novel neutralization assays were found to be
ighly sensitive, reproducible, and rapid, allowing the
omplete assay to be carried out within a time frame of
8–72 h (Fig. 1).
It has been reported that ICAM-1-dependent cellular
dhesion diminishes the potency of antibodies known to
brogate HIV-1-mediated syncytium formation (Berman
nd Nakamura, 1994). We were thus wondering whether
he incorporation of host cell membrane ICAM-1 proteins
n progeny HIV-1 particles could also attenuate the over-
ll potency of neutralizing agents such as sCD4 and
nti-gp120 antibodies (monoclonal and polyclonal). Our
nitial experiments indicated that ICAM-1-bearing prog-
ny viruses were not less sensitive to neutralization by
CD4 and three monoclonal anti-gp120 antibodies (i.e.,
105, 0.5b, and 4.8D) when target cells were expressing
FA-1 molecules in a low-affinity state for ICAM-1 (Figs.
and 3A). Our observations hence do not support a
revious study that has shown that ICAM-1-bearing
IV-1 particles are slightly less susceptible to neutral-
zation by F105 than isogenic virions devoid of host-
ncoded ICAM-1 (Rizzuto and Sodroski, 1997). We be-
is diminished by the acquisition of host-encoded ICAM-1 proteins by
1/POS (h) progeny virions (10 ng of p24) were incubated for 30 min at
054, panels A and D; P032, panels B and E; P017, panels C and F). In
pretreated with 1 mg/ml NKI-L16 for 30 min at 37°C (D–F). Cells were
r an additional 48 h at 37°C. Cells were lysed, and luciferase activity
legend to Fig. 2. Results are the mean 6 SD for triplicate samples andiduals
ICAM-
jects (P
were
ceed foieve that such a discrepancy might be related to the use
f a different cellular target in the neutralization assay.
499ENV-INCORPORATED ICAM-1 AND HIV-1 NEUTRALIZATIONA novel aspect of this work is the role played by the
conformational state of LFA-1 with regard to neutraliza-
tion sensitivity of ICAM-1-bearing HIV-1 particles. This
parameter was studied based on our previous data in-
dicating that expression of the high-affinity LFA-1 form
significantly enhanced the susceptibility of target cells to
infection by ICAM-1/POS virions without affecting the
infection by ICAM-1/NEG virions (Fortin et al., 1998). It is
quite clear from our results that surface expression of the
activated LFA-1 form on target cells reduces the sensi-
tivity to neutralization of ICAM-1/POS viruses but not of
isogenic ICAM-1/NEG HIV-1 particles. It should be noted
that such a higher resistance depends on the type of
neutralizing agents used in the assay because a dimin-
FIG. 5. Diminished sensitivity to neutralization is also observed using
ICAM-1-bearing viruses pseudotyped with macrophage-tropic enve-
lope proteins. Similar amounts of ICAM-1/NEG (E) and ICAM-1/POS
(h) luciferase-encoding progeny virions pseudotyped with the enve-
lope protein from JR-FL (5 ng of p24) were incubated for 30 min at 37°C
with twofold serial dilutions of sera from P054. PM1 target cells were
either left untreated (A) or pretreated with 1 mg/ml NKI-L16 for 30 min
at 37°C (B). Cells were next added to the virus–sera mixture, and
infection was allowed to proceed for an additional 72 h at 37°C. Cells
were lysed, and luciferase activity was monitored. Inhibition of virus
infection was evaluated as described in the legend to Fig. 2. Results
are the mean 6 SD for triplicate samples and are representative of
three independent experiments.ished neutralization sensitivity is observed with F105 but
not with sCD4 and the other monoclonal anti-gp120 an-tibodies (i.e., 0.5b and 4.8D) (Figs. 2 and 3). The under-
lying mechanism or mechanisms responsible for this
observation are unclear but might be related to the
epitope specificity (linear versus conformational), the
binding affinity, and/or the mode of neutralization by the
studied inhibiting agents. F105 recognizes a conforma-
tional epitope of gp120 (Posner et al., 1993), and 0.5b
binds to a linear determinant of the V3 loop (Matsushita
et al., 1988). The mechanism of action of F105 relies on
its ability to directly block the binding of HIV-1 to CD4-
expressing cells, whereas 0.5b inhibits at a postbinding
step. On the other hand, 4.8D and sCD4, which are not
affected by the activated state of LFA-1, neutralize virus
infectivity by inducing a shedding of gp120 (Ugolini et al.,
1997). In the presence of target cells bearing activated
LFA-1 molecules, the increased resistance to neutraliza-
tion is solely due to the interaction between LFA-1 and
ICAM-1, as abrogation of this interaction by pretreatment
of the virions with a blocking anti-ICAM-1 antibody ren-
dered ICAM-1/POS viruses as sensitive as ICAM-1/NEG
virions to neutralization (Fig. 3C).
Even though the observed differences were not signif-
icant, ICAM-1/POS progeny viruses were found to be
harder to neutralize by sera from HIV-1-infected individ-
uals than virus preparations devoid of host-derived
ICAM-1 when using 1G5 cells expressing a low-affinity
form of LFA-1 (Figs. 4A–4C). The degree of neutralizabil-
ity of ICAM-1/POS virions by human serum samples was
more dramatically modified when using 1G5 target cells
expressing the activated LFA-1 form (Figs. 4D–4F). The
resistance ratios [(IC50 ICAM-1/POS)/(IC50 ICAM-1/NEG)]
that were obtained when using 1G5 cells bearing the
activated LFA-1 form varied between the different studied
sera of the HIV-1-infected individuals (Table 1). The pre-
cise reasons for this observation are not clear at the
moment, and further study is warranted to shed light onto
this matter.
In sera from HIV-1-infected patients, most of the neu-
tralizing activity directed against T-cell line-adapted
strains (e.g., HIV-1NL4-3) is targeted against two specific
regions of gp120: the CD4 binding site (CD4bs) and the
V3 loop (Ugolini et al., 1997). Based on these observa-
tions and our data, it is tempting to speculate that anti-
bodies specific for CD4bs and V3 domain will be more
affected in their capacity to neutralize virus infection in
the presence of secondary interactions occurring be-
tween virally embedded host ICAM-1 and the high-affin-
ity conformational state of LFA-1 expressed on the sur-
face of target cells. This postulate is based on the ob-
tained results with F105 and sera from seropositive
patients that demonstrated that the neutralizing ability of
these agents is more sensitive to the activated state of
LFA-1 than for both 4.8D and sCD4, two agents known to
mediate shedding of gp120. The strong additional inter-
action between virally acquired host ICAM-1 proteins
and the activated LFA-1 form probably helps the virus to
t
g
I
a
k
I
c
m
2
t
b
E
s
r
e
m
1
(
p
e
T
B
A
b
t
b
f
a
C
e
0
500 FORTIN ET AL.attach to the cell despite the presence of antibodies that
reduce the efficacy of the initial contact between gp120
and CD4.
We have also been able to demonstrate that the effect
of the ICAM-1/LFA-1 interaction on neutralization sensi-
tivity by human sera was observed with viral entities
bearing either T- (X4) or macrophage-tropic (R5) enve-
lope proteins. This is in agreement with recent studies
that have established that sera-mediated neutralization
of HIV-1 is independent of the coreceptor use (LaCasse
et al., 1998; Montefiori et al., 1998; Trkola et al., 1998).
This observation is highly relevant due to the proposed
crucial role played by HIV-1 R5 strains in sexual trans-
mission and establishment of infection (Cornelissen et
al., 1995; Veenstra et al., 1995).
We and others have reported that depending on the
infected cell type, the specific nature of host-derived
molecules acquired by budding HIV-1 particles varies
(Bastiani et al., 1997; Cantin et al., 1996; Frank et al.,
1996). More importantly, it has been demonstrated that
the sensitivity of low-passage clinical and laboratory
strains of HIV-1 to neutralization by human sera is influ-
enced by the cell type in which the progeny virions are
propagated (Sawyer et al., 1994). Overall, these studies
and the present observations led us to postulate that the
neutralization sensitivity of HIV-1 is indeed modified to
some extent by host cell constituents acquired by nas-
cent viruses.
In summary, we have demonstrated that the physical
presence of host-derived ICAM-1 proteins on HIV-1 dif-
ferently modulates neutralization sensitivity of HIV-1 par-
ticles, depending on both the type of inhibitory agents
used and the conformational state of LFA-1 on the target
cells. In light of the data that we have gathered with
polyclonal sera form HIV-1-infected persons, it seems
reasonable to postulate that infection with ICAM-1-bear-
ing HIV-1 particles is harder to inhibit and that the neu-
tralization sensitivity of such virions is markedly dimin-
ished if target cells are expressing a high-affinity form of
LFA-1 for ICAM-1 on their surface. The T-cell receptor-
mediated activation of LFA-1 is a more transient event
than the NKI-L16-induced LFA-1 activation used in the
present work. However, in HIV-1-infected individuals, the
very high proportion of activated T-lymphocytes in sec-
ondary lymphoid organs (Pantaleo et al., 1993a, 1993b)
leads us to propose that the modulation of virus neutral-
ization sensitivity by the ICAM-1/LFA-1 interaction might
play a role in the HIV-1 immunopathogenesis. Our data
further emphasize the role of host factors in the patho-
genesis of HIV-1 infection and could also help in the
design of new vaccination strategies, as recently
stressed by Hioe et al. (1998), particularly after taking into
account the effect of the activated state of LFA-1 rela-
tively to the type of antibodies used to mediate neutral-
ization. mMATERIALS AND METHODS
Cells and plasmids
The 1G5 T-cell line, a Jurkat E6–1 derivative that har-
bors two stably integrated constructs constituted of the
luciferase reporter gene under the control of the HIV-1SF2
LTR element (Aguilar-Cordova et al., 1994), was obtained
hrough the AIDS Research and Reference Reagent Pro-
ram (Division of AIDS, National Institute of Allergy and
nfectious Diseases, National Institutes of Health). PM1,
clonal derivative of HUT 78 (Lusso et al., 1995), was
indly provided by Dr. P. Lusso (The San Rafael Scientific
nstitute, Milan, Italy). These cells were maintained in
omplete culture medium made of RPMI 1640 supple-
ented with 10% FBS (Hyclone Laboratories, Logan, UT),
mM glutamine, 100 U/ml penicillin G, and 100 mg/ml
streptomycin. We have also used human embryonic kid-
ney 293T cells, which express the simian virus 40 large
T antigen (Pear et al., 1993). This cell line was maintained
in DMEM supplemented with 10% FBS, 2 mM L-glu-
amine, 100 U/ml penicillin G, and 100 mg/ml streptomy-
cin and was kindly provided by Dr. Warner C. Greene
(The J. Gladstone Institutes, San Francisco, CA). Flow
cytometric analysis revealed that 1G5 and PM1 cells
express high levels of LFA-1 on their surface, whereas
293T cells are negative for ICAM-1 (data not shown).
pNL4-3 is a full-length infectious molecular clone of
HIV-1 (Adachi et al., 1986). This vector has been provided
y the AIDS Repository Reagent Program. pNL4-3-Luc-
2R1, which is derived from pNL4-3, contains a frame-
hift mutation in the env gene and has the nef gene
eplaced by the luciferase reporter gene. pcDNA-1/JR-FL
nv vector codes for the envelope proteins from the
acrophage-tropic (R5) JR-FL viral strain (Deng et al.,
996). Both plasmids are kind gifts from Dr. N. Landau
The Salk Institute for Biological Studies, La Jolla, CA).
CD1.8 is an eukaryotic expression vector containing the
ntire human ICAM-1 cDNA and was obtained from Dr.
imothy A. Springer (The Center for Blood Research,
oston, MA) (Staunton et al., 1988).
ntibodies, human serum samples, and sCD4
The anti-ICAM-1 antibody (anti-CD54) RR1/1.1.1 has
een previously shown to inhibit ICAM-1/LFA-1 interac-
ion (Marlin and Springer, 1987) and was kindly provided
y Dr. Robert Rothlein (Boehringer Ingelheim, Ridge-
ields, CN) (Rothlein et al., 1986). The LFA-1-activating
ntibody NKI-L16 (anti-CD11a) was obtained from Dr.
arl C. Figdor (University Hospital Nijmegen, The Neth-
rlands) (Keizer et al., 1988). The monoclonal antibody
.5b mapping to amino acids 308–331 from HIV-1IIIB
gp120 (Matsushita et al., 1988), 4.8D, a human monoclo-
nal antibody specific for a conformational epitope of
gp120 (Thali et al., 1993), and F105, another human
onoclonal antibody directed against a conformational
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501ENV-INCORPORATED ICAM-1 AND HIV-1 NEUTRALIZATIONepitope of gp120 mapping to the CD4 binding site (Pos-
ner et al., 1993), were obtained from Dr. Shuzo Matsu-
shita, James Robinson, and Marshall Posner, respec-
tively, through the AIDS Repository Reagent Program.
Individual heat-inactivated sera from three HIV-1-infected
subjects at different stages of the disease were also
used in this study. Serum samples were obtained from
HIV-1-infected persons followed at the HIV/AIDS Clinic of
the Centre Hospitalier de l’Universite´ Laval (Quebec City,
Canada). Informed consent was obtained from each in-
dividual before their blood was collected. All serum sam-
ples were heat inactivated at 56°C for 30 min before use.
Recombinant sCD4 was also obtained through the AIDS
Repository Reagent Program from Dr. Ray Sweet (Smith-
Kline Beecham) (Arthos et al., 1989).
Virus stocks
Viral particles differing only by the absence or the
presence of host-derived ICAM-1 proteins on their sur-
faces were produced by CaPO4 transfection of pNL4-3
(10 mg) or, for pseudotyped virions, pNL4-3-Luc-E2R1(5
mg) with pcDNA-1/JR-FL(5 mg), as described previously
(Fortin et al., 1997; Paquette et al., 1998). These transfec-
tions were done in the absence or the presence of 5 mg
of the ICAM-1 expression vector to produce ICAM-1/NEG
or ICAM-1/POS virus particles, respectively. Virus stocks
were normalized for virion content using a commercial
assay for the major viral core protein p24 (Organon
Teknika, Durham, NC).
Neutralization assay
Fixed amounts of ICAM-1/NEG and ICAM-1/POS virus
stocks (5–10 ng of p24) were either left untreated or
incubated in the presence of increasing concentrations
of individual sera, monoclonal anti-gp120 antibodies, or
sCD4. These incubations were performed at 37°C in
96-well plates in a final volume of 100 ml for 30 min. In
ome experiments, target cells were either left untreated
r were treated with the LFA-1-activating antibody NKI-
16 at 1 mg/ml for 30 min at 37°C. After this incubation
period, 100 ml of the cell suspension (1 3 106 cells/ml for
G5, 5 3 105 cells/ml for PM1) was added to each well,
nd the plates were incubated at 37°C before lysis (48 h
or 1G5 and 72 h for PM1). The level of virus infection
as quantified by monitoring virus-encoded luciferase
ctivity in the infected cells as described previously (For-
in et al., 1997).
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